Synthesis and UV studies of a small library of 6-aryl-4-hydroxy-2- pyrones. A relevant structural feature for the inhibitory property of arisugacin against acetylcholinesterase

Tetrahedron

Volumn 55, Issue 48, 1999, Pages 13683-13696

  Douglas, Christopher J ^a   Sklenicka, Heather M ^a   Shen, Hong C ^a   Mathias, David S ^a   Degen, Shane J ^a   Golding, Geoffrey M ^a   Morgan, Christopher D ^a   Shih, Regina A ^a   Mueller, Kristen L ^a   Seurer, Lisa M ^a   Johnson, Erik W ^a   Hsung, Richard P ^a  

^a NONE

Author keywords

Electronic Effects; Electronic Spectra; NMR; Pyrones

Indexed keywords

ARISUGACIN; CHOLINESTERASE INHIBITOR; PYRONE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CHEMICAL MODIFICATION; CHEMICAL REACTION; DRUG STRUCTURE; DRUG SYNTHESIS; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SPECTRAL SENSITIVITY; STRUCTURE ACTIVITY RELATION; ULTRAVIOLET SPECTROSCOPY;

EID: 0033607796     PISSN: 00404020     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0040-4020(99)00847-9     Document Type: Article

References (35)

1. 4. For a review see: Romines, K. R.; Chrusciel, R. A. Current Med. Chem. 1995, 2, 825.
2. 5. For recent reports see: a) Fors, K. S.; Gage, J. R.; Heier, R. F.; Kelly, R. C.; Perrault, W. R. Wicnienski, N. J. Am. Chem. Soc. 1998, 63, 7348.
3. b) Thaisrivongs, S.; Janakiraman, M. N.; Chong, K.-T.; Tomich, P. K.; Dolak, L. A.; Turner, S. R.; Strohbach, J. W.; Lynn, J. C.; Horng, M.-M.; Hinshaw, R. R.; Watenpaugh, K. D. J. Med. Chem. 1996, 39, 2400.
4. c) Vara Prasad, J. V. N.; Tummino, P. J.; Ferguson, D.; Saunders, J.; Vander Roest, S.; McQuade, T. J.; Heldsinger, A.; Reyner, E. L.; Stewart, B. H.; Guttendorf, R. J.; Para, K. S.; Lunney, E. A.; Gracheck, S. J.; Domagala, J. M. Biochemical & Biophy. Res. Commun. 1996, 221, 815.
5. 6. For biological activities of pyripyropenes see: a) Tomoda, H.; Tabata, N.; Yang, D. J.; Namatame, I.; Tanaka, H.; Omura, S.; Kaneko, T. J. Antibiotics 1996, 49, 292.
6. b) Obata, R.; Sunazuka, T.; Li, Z. R.; Tian, Z. M.; Harigava, Y.; Tabata, N.; Tomoda, H.; Omura, S. J. Antibiotics 1996, 49, 1133.
7. 7. For total syntheses of pyripyropene-A and -E see: a) Smith, A. B. III; Kinsho, T.; Sunazuka, T.; Õmura, S. Tetrahedron Lett. 1996, 6461, and references cited within.
8. b) Nagamitsu, T.; Sunazuka, T.; Obata, R.; Tomoda, H.; Tanaka, H.; Harigaya, Y.; Omura, S.; Smith, A. B. III. J. Org. Chem. 1995, 60, 8126.
9. c) Parker, K. A; Resnick, L. J. Org. Chem. 1995, 60, 5726.
10. 8. Obata, R.; Sunazuka, T.; Tian, Z.; Tomoda, H.; Harigaya, Y.; Õmura, S.; Smith, A. B. III. Chemistry Lett. 1997, 935.
11. 9. For a leading reference see: Otoguro, K.; Kuno, F.; Õmura, S. Pharmacol. Ther. 1997, 76, 45.
12. 10. For an account on the DE-ring of a structurally related natural product territrem B see: Peng, F.-C., J. Nat. Prod. 1995, 58, 857.
13. 11. Alzheimer, A. Gesamte Psychiatrie 1907, 64, 1264.
14. 12. a) Aisen, P. S.; Davis, K. L. Neurology 1997, 48(5 suppl 6), S35.
15. b) Lansbury, P. T. Jr. Acc. Chem. Res. 1996, 29, 317.
16. 13. For a review see: Giacobini, E.; Becker, R., Eds. Alzheimer's Disease: From Molecular Biology to Therapy. Birkhauser: Boston, 1997.
17. 14. As an inhibitor of AChE, arisugacin could serve as a therapuetic based on the Cholinergic Hypothesis. For a reference on anti-dementia therapeutics based on the Cholinergic Hypothesis see: Perry, E. K., Brit. Med. Bullet. 1986, 42, 63.
18. 15. For other studies related to arisugacin see: Hua, D. H.; Chen, Y.; Sin, H.-S.; Maroto, M. J.; Robinson, P. D.; Newell, S. W.; Perchellet, E. M.; Ladesich, J. B.; Freeman, J. A.; Perchellet, J.-P.; Chiang, P. K. J. Org. Chem. 1997, 62, 6888.
19. 16. a) Hsung, R. P. J. Org. Chem. 1997, 62, 7904.
20. b) Hsung, R. P. Heterocycles 1998, 48, 421.
21. c) Granum, K. G.; Merkel, G.; Mulder, J. A.; Debbins, S. A.; Hsung, R. P. Tetrahedron Lett. 1998, 9597.
22. d) Degen, S. J.; Mueller, K. L.; Shen, H. C.; Mulder, J. A.; Golding, G. M.; Wei, L.-L.; Zificsak, C. A.; Hsung, R. P. Bioorg. & Med. Chem. Lett. 1999, 973.
23. e) Wei, L.-L.; Xiong, H.; Douglas, C. J.; Hsung, R. P. Tetrhedron Lett. 1999, in press.
24. f) Hsung R. P.; Zificsak, C. A.; Wei, L.-L.; Zehner, L. R.; Park, F.; Kim, M.; Tran, M. J. Org. Chem. 1999, submitted.
25. 17. a) Hsung, R. P.; Shen, H. C.; Douglas, C. J.; Morgan, C. D.; Degen, S. J.; Yao, L. J. J. Org. Chem. 1999, 64, 690.
26. b) Hsung, R. P.; Wei, L.-L.; Sklenicka, H. M.; Douglas, C. J.; McLaughlin, M. J.; Mulder, J. A.; Yao, L. J. Organic Letters 1999, 1, 509.
27. 18. Summers, W. K.; Majovski, L. V.; Marsh, G. M.; Tachiki, K.; Kling, A. N. Engl. J. Med. 1986, 315, 1241.
28. 19. Inoue, A.; Kawai, T.; Wakita, M.; Iimura, Y.; Sugimoto, H.; Kawakami, Y. J. Med. Chem. 1996, 39, 4460.
29. 20. a) Kozikowski, A. P.; Campiani, G.; Nacci, V.; Sega, A.; Saxena, A.; Doctor, B. P. J. Chem. Soc. Perkin Trans. I 1996, 1287.
30. b) Xia, Y.; Kozikowski, A. P. J. Am. Chem. Soc. 1989, 111, 4116.
31. 21. Davis, K. L.; Mohs, R. C.; Tinklenberg, J. R. N. Engl. J. Med. 1979, 301, 946.
32. 22. Fulton, B.; Benfield, P. Drugs and Aging 1996, 60.
33. 23. Summers, W. K.; Koehler, A. L.; Marsh, G. M.; Tachiki, K.; Kling, A. Lancet 1989, 729.
34. 24. Silverstein, R. M.; Bassler, G. C.; Morrill, T. C. Spectrometric Indentification of Organic Compounds, John Wiley & Sons, INC: New York, 1991.
35. 25. Still, W. C.; Kahn, M.; Mitra, A. J. Org. Chem. 1978, 43, 2923.